Literature DB >> 22150076

Cancer's unequal impact on incomes in Norway.

Astri Syse1, Marianne Tønnessen.   

Abstract

BACKGROUND: At a group level, cancer results in reduced labor earnings. Public benefits common to welfare states may, however, compensate for all or parts of the decline in earnings. Norwegian cancer survivors' incomes, including both labor earnings and compensatory welfare benefits, were compared to those of the cancer-free population to assess potential welfare consequences of cancer. Possible modifying effects of parental and marital status, education, prior earnings and age were assessed in depth.
MATERIAL AND METHODS: Log-linear regression models were used to estimate incomes across different sociodemographic variables using register data covering the entire Norwegian population 40-59 years old with any income in 2008, 536 600 men and 502 500 women, of whom more than 17,000 were diagnosed with cancer in 2000-2007.
RESULTS: Compared to the cancer-free general population, cancer was associated with a modest 7% decline in incomes overall. The decline was, however, significantly associated with sociodemographic factors, marital status exempted. Childless men with low education and low prior earnings were most adversely affected. Lymphomas and lung cancer accounted largely for these unfavorable effects.
CONCLUSIONS: Declines in earnings after cancer are to a large degree compensated by the Norwegian welfare state, and incomes overall are only modestly decreased among cancer survivors compared to the general population. Persons with multiple unfavorable sociodemographic characteristics experience particularly low incomes after cancer. This is of concern in a supposedly egalitarian society with public health care and antidiscrimination acts in place. Welfare state interventions, i.e. work reintegration efforts and/or compensations for labor earning drops, directed specifically towards these subgroups might be warranted.

Entities:  

Mesh:

Year:  2011        PMID: 22150076     DOI: 10.3109/0284186X.2011.640710

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  A controlled cohort study of long-term income in colorectal cancer patients.

Authors:  Beate Hauglann; Jūratė Saltytė Benth; Sophie D Fosså; Kjell M Tveit; Alv A Dahl
Journal:  Support Care Cancer       Date:  2014-05-13       Impact factor: 3.603

2.  A controlled study of income development for breast cancer survivors in Norway.

Authors:  Jūratė Šaltytė Benth; Fredrik A Dahl; Hilde Lurås; Alv A Dahl
Journal:  J Cancer Surviv       Date:  2013-12-19       Impact factor: 4.442

Review 3.  The global impact of non-communicable diseases on households and impoverishment: a systematic review.

Authors:  Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Taulant Muka; David Imo; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

4.  Income loss after a cancer diagnosis in Germany: An analysis based on the socio-economic panel survey.

Authors:  Diego Hernandez; Michael Schlander
Journal:  Cancer Med       Date:  2021-05-10       Impact factor: 4.452

5.  Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period.

Authors:  Helen Egestad; Carsten Nieder
Journal:  Int J Circumpolar Health       Date:  2015-01-22       Impact factor: 1.228

6.  The long-term financial consequences of breast cancer: a Danish registry-based cohort study.

Authors:  Laura Schärfe Jensen; Charlotte Overgaard; Henrik Bøggild; Jens Peter Garne; Thomas Lund; Kim Overvad; Kirsten Fonager
Journal:  BMC Public Health       Date:  2017-10-30       Impact factor: 3.295

7.  Inequality in income change among cancer survivors five years after diagnosis: Evidence from a French national survey.

Authors:  Caroline Alleaume; Marc-Karim Bendiane; Patrick Peretti-Watel; Anne-Déborah Bouhnik
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.